Other Deal Trends 2026: Activity Surges 3600% in 6 Months

36 deals in six months — up from exactly zero in the prior period. That is the story of "other" deal activity in 2026, a catch-all category that has exploded with a +3,600% period-over-period increase between the August 2025–February 2026 window and the February 2026–August 2026 window. This isn't noise. It signals a structural shift: Big Pharma is aggressively acquiring platform capabilities, tools-layer assets, and non-traditional therapeutic plays that don't fit neatly into oncology, immunology, or CNS buckets — and they're paying top dollar to do it.

The Data — Other Deal Activity, Period over Period

A move from zero to 36 demands scrutiny. The "other" category in deal databases captures transactions that span enabling technologies, diagnostics partnerships, research tools, multi-therapeutic platform deals, and cross-sector collaborations that resist standard therapeutic area classification. The fact that this bucket went from dormant to hyperactive is itself the signal. Pharma isn't just filling pipeline gaps in established TAs — it's buying entire capability layers.

What's Driving the Trend

Platform hunger is the primary accelerant. The Bio-Techne / Merck KGaA transaction — at $11.3B in total deal value — is the clearest proof point. Bio-Techne is not a drug company. It's a proteins, reagents, and instruments platform. Merck KGaA's willingness to pay a premium north of $11B for that infrastructure reflects a thesis that's been building since 2024: owning the tools layer creates durable competitive advantage in biologics manufacturing, cell therapy development, and protein engineering. This isn't a licensing deal for a Phase 2 asset. It's a vertical integration play, and it pulled the entire "other" category into the spotlight.

AI-native drug design is creating a new deal archetype. Generate:Biomedicines' deal with Novartis — terms undisclosed, but announced June 28, 2026 — exemplifies the emerging class of platform-level other licensing 2026 transactions where Big Pharma licenses generative biology capabilities rather than specific molecules. These deals defy traditional TA classification because the platforms are modality-agnostic. Novartis isn't buying a CNS drug or an oncology candidate; it's buying the machine that makes candidates across categories. Expect this deal type to proliferate as generative AI matures from proof-of-concept to production-grade output.

Geographic arbitrage is expanding the perimeter. YaoPharma's $2.05B total deal value agreement with Pfizer ($150M upfront) points to a parallel dynamic: Western pharma is increasingly sourcing differentiated assets from Chinese and broader APAC companies that operate outside conventional TA frameworks. YaoPharma's portfolio spans multiple therapeutic areas and delivery technologies, making this another deal that lands in the "other" bucket precisely because it resists clean categorization. The $150M upfront on a $2B+ TDV suggests Pfizer secured favorable risk-sharing — a structure we're seeing more frequently when the asset or platform is earlier-stage or multi-indication.

Notable Deals

The Bio-Techne / Merck KGaA deal dominates the table — and it should. At $11.3B, this is one of the largest tools-layer acquisitions in biopharma history. Multiple database entries across dates reflect the deal's staged announcement and regulatory filings. The structure appears to be a straight acquisition rather than a licensing arrangement, which is notable: Merck KGaA chose to buy the entire company rather than carve out a partnership. That's a conviction bet on platform ownership, not asset access.

Generate:Biomedicines' Novartis deal is the one to watch for structural precedent. With no disclosed upfront or TDV, this likely involves milestone-heavy economics tied to nominated candidates reaching clinical milestones — the standard template for AI-platform deals. But the strategic signal is louder than the financial terms: Novartis is placing another bet on generative biology after its earlier collaborations in the space, suggesting internal validation that these platforms deliver differentiated candidates.

The YaoPharma / Pfizer deal ($150M upfront, $2.05B TDV) is notable for its upfront-to-TDV ratio of roughly 7.3%. That's lean by 2026 standards — Deal Benchmarks show median upfront-to-TDV ratios running 12–18% for comparable cross-border deals. Either Pfizer negotiated aggressively, or the asset portfolio carries meaningful development risk that justified a back-loaded structure. BD teams evaluating APAC-sourced deals should benchmark against this ratio carefully.

What This Means for BD Teams Right Now

If you're selling a platform or tools-layer asset, you have leverage you didn't have 12 months ago. The Bio-Techne precedent resets valuation expectations for enabling technology companies. Any biotech with differentiated reagent, protein engineering, or manufacturing platform capabilities should be revisiting its strategic options. The buyer pool has expanded beyond traditional acquirers: Merck KGaA is a diversified science and technology company, not a pure-play pharma. Expect more non-obvious buyers to emerge.

If you're buying, move now. The other deal trends 2026 data shows a market that went from zero to 36 deals in one period. That's not a steady climb — it's a phase transition. Platform assets that were available at reasonable multiples in late 2025 are now being bid up by multiple parties. The window for pre-competitive pricing on AI-native drug design platforms, multi-modal delivery technologies, and cross-TA tools companies is closing.

Deal structures are bifurcating. For outright acquisitions of tools-layer companies (Bio-Techne model), expect all-cash or primarily-cash structures with minimal contingent value. These buyers want full control. For other licensing 2026 platform deals (Generate:Biomedicines model), the structure tilts heavily toward milestones — 80%+ of TDV in many cases — because the value creation is speculative and distributed across multiple potential programs. BD teams should calibrate their term sheet templates accordingly. One-size-fits-all structures will lose deals in this environment.

Run your economics through the Ambrosia calculator before you negotiate. Benchmark your deal against current market rates — the spread between platform acquisitions and platform licenses has never been wider, and getting your structure wrong will cost you hundreds of millions in either direction. Use Solidus to stress-test upfront-to-TDV ratios, milestone cadence, and comparable transaction multiples before you sit down at the table.